1. Home
  2. BIVI vs HYFM Comparison

BIVI vs HYFM Comparison

Compare BIVI & HYFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BIVI
  • HYFM
  • Stock Information
  • Founded
  • BIVI 2013
  • HYFM 1977
  • Country
  • BIVI United States
  • HYFM United States
  • Employees
  • BIVI N/A
  • HYFM N/A
  • Industry
  • BIVI Biotechnology: Pharmaceutical Preparations
  • HYFM Industrial Machinery/Components
  • Sector
  • BIVI Health Care
  • HYFM Industrials
  • Exchange
  • BIVI Nasdaq
  • HYFM Nasdaq
  • Market Cap
  • BIVI 15.0M
  • HYFM 17.3M
  • IPO Year
  • BIVI N/A
  • HYFM 2020
  • Fundamental
  • Price
  • BIVI $6.03
  • HYFM $4.34
  • Analyst Decision
  • BIVI
  • HYFM Hold
  • Analyst Count
  • BIVI 0
  • HYFM 2
  • Target Price
  • BIVI N/A
  • HYFM $7.00
  • AVG Volume (30 Days)
  • BIVI 66.5K
  • HYFM 11.2K
  • Earning Date
  • BIVI 09-29-2025
  • HYFM 08-12-2025
  • Dividend Yield
  • BIVI N/A
  • HYFM N/A
  • EPS Growth
  • BIVI N/A
  • HYFM N/A
  • EPS
  • BIVI N/A
  • HYFM N/A
  • Revenue
  • BIVI N/A
  • HYFM $176,650,000.00
  • Revenue This Year
  • BIVI N/A
  • HYFM $5.45
  • Revenue Next Year
  • BIVI N/A
  • HYFM $5.33
  • P/E Ratio
  • BIVI N/A
  • HYFM N/A
  • Revenue Growth
  • BIVI N/A
  • HYFM N/A
  • 52 Week Low
  • BIVI $5.74
  • HYFM $1.50
  • 52 Week High
  • BIVI $75.00
  • HYFM $8.55
  • Technical
  • Relative Strength Index (RSI)
  • BIVI 34.02
  • HYFM 56.32
  • Support Level
  • BIVI $7.24
  • HYFM $3.88
  • Resistance Level
  • BIVI $7.75
  • HYFM $4.73
  • Average True Range (ATR)
  • BIVI 0.72
  • HYFM 0.34
  • MACD
  • BIVI -0.10
  • HYFM -0.01
  • Stochastic Oscillator
  • BIVI 8.78
  • HYFM 60.20

About BIVI BioVie Inc.

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

About HYFM Hydrofarm Holdings Group Inc.

Hydrofarm Holdings Group Inc is a distributor and manufacturer of agriculture equipment and supplies. Some of its products includes lighting solutions, growing media (i.e., premium soils and soil alternatives), nutrients, equipment, and supplies sold under proprietary, exclusive/preferred brands, or non-exclusive/distributed brands. The business is organized into two operating segments, the U.S. and Canada.

Share on Social Networks: